An open-label, multi-center, extension study to evaluate the long-term safety, tolerability and preliminary efficacy of evenamide as add-on treatment in patients with treatment-resistant schizophrenia (TRS) not responding adequately to their current antipsychotic medication.
Latest Information Update: 26 Jun 2024
At a glance
- Drugs Evenamide (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Newron Pharmaceuticals
- 24 Jun 2024 According to a Newron Pharmaceuticals media release, According to a Newron Pharmaceuticals media release, data form this trial were presented Investor Day 2024 in New York City.
- 08 Apr 2024 According to a Newron Pharmaceuticals media release, data from this study were presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) from 3-7 April in Florence, Italy.
- 04 Jan 2024 Final 1-year results presented in a Newron Pharmaceuticals Media Release.